Prednisone in Adults With an Immune-Mediated Subtype of Autism Spectrum Disorder

NCT06934915 | Not Yet Recruiting Early Phase 1 DMC FDA Drug

• 1 other identifier: 2024P003682
• Study Type: interventional
• Target: 32
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to learn how prednisone affects adults with autism spectrum disorder (ASD). It will also learn about the safety of prednisone. The main questions it aims to answer are:

• How does prednisone affect the core features and associated target symptoms of ASD in adults with an immune-mediated subtype of ASD?
• Is prednisone safe for autistic adults without causing too many side effects?
• Does this study warrant larger trials studying anti-inflammatory drugs in this subject population? Researchers will compare the drug prednisone to a placebo (a look-alike substance that contains no drug) to see how prednisone affects autistic adult males. Participants will:
• Visit the clinic 2 times for a screening and baseline visit.
• Take prednisone or a placebo every day for 16 weeks.
• Visit the clinic 2 times for checkups, tests, questionnaires, and dose changes, and 1 time for a follow-up visit 4 weeks after stopping the study drug.
• Provide blood and urine samples for testing up to 4 times.
• Complete 8 remote calls every 1-2 weeks for checkups and dose changes.
• Keep a diary of the dose and times they take the study drug every day and any symptoms or side effects they experience.

Conditions

Autism Spectrum Disorder; Autism Spectrum Disorders; Autism; Autistic Disorder

Keywords

Autism Spectrum Disorder; Autistic Disorder; Autism; Autoimmunity; Autoimmune Disorders; Inflammation; Neuroinflammation; Anti-Inflammatory Agents; Corticosteroids; Glucocorticoids; Prednisone

Outcome Measures

Primary Outcomes (1)

• Mean difference in Clinical Global Impressions-Improvement (CGI-I) ratings between the prednisone and placebo groups at Visit 9

  Mean difference in CGI-I ratings between the prednisone and placebo groups at Visit 9 (efficacy). The CGI-I is a single-item measure of global symptomatic improvement compared to baseline. Improvement is rated on a 7-point scale, ranging from 1 ("Very much improved") to 7 ("Very much worse"). A global domain score of 1 ("Very much improved") or 2 ("Much improved") on the CGI-I scale will constitute a positive treatment response.

  Baseline to Week 10

Secondary Outcomes (4)

• Number of randomized study participants

  At Baseline

• Percent of participants enrolled at Visit 9 (Week 10) and contributing a visit 9 CGI-I rating

  Baseline to Week 10

• Percent of participants randomized to prednisone experiencing serious adverse events (SAEs) probably or definitely related to medication

  Baseline to Week 20

• Percent of participants randomized to prednisone who complete a ten-week course of study drug

  Baseline to Week 10

Other Outcomes (5)

• Change in Irritability Subscale Score of the Aberrant Behavior Checklist-Community (ABC-C)

  Baseline to Week 10

• Change in Social Withdrawal Subscale Score of the ABC-C

  Baseline to Week 10

• Change in Stereotypic Behavior Subscale Score of the ABC-C

  Baseline to Week 10

Study Arms (2)

Prednisone

EXPERIMENTAL

Eligible participants will receive prednisone for up to 16 weeks. The treatment period consists of 3 structured phases: Dose Escalation (Weeks 1-5), Optimal Dose Maintenance (Weeks 6-10), and Gradual Dose Reduction (Weeks 11-16).

Drug: Prednisone

Placebo

PLACEBO COMPARATOR

Eligible participants will receive a matching placebo for up to 16 weeks. The treatment period consists of 3 structured phases: Dose Escalation (Weeks 1-5), Optimal Dose Maintenance (Weeks 6-10), and Gradual Dose Reduction (Weeks 11-16).

Drug: Placebo

Interventions

Prednisone DRUG

Starting dose: 5 mg daily. Maximum dose: 60 mg daily. Dosage forms: 5 mg, 10 mg, and 20 mg capsules.

Prednisone

Placebo DRUG

Capsules identical in size and appearance to those containing prednisone. Placebo capsules contain inactive ingredients.

Placebo

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• to 50 years of age (inclusive) and assigned male at birth.
• Diagnostic Statistical Manual of Mental Disorders (DSM), Fourth Edition, Text Revision (DSM-IV-TR) diagnosed autistic disorder, and DSM, Fifth Edition, Text Revision (DSM-5-TR) diagnosed autism spectrum disorder (ASD), level 2 or 3. A qualified (board-eligible or board-certified) psychiatrist or psychologist, with experience in diagnostic determinations of ASD, will make a final diagnostic determination based on clinical history, clinical observations, medical records, mental status exams, and screening measures.
• A Clinical Global Impression-Severity (CGI-S) rating ≥ 4 ("Moderate") at screening (and baseline).
• A non-verbal IQ in the range of moderate intellectual disability or higher (≥ 35), as measured by the non-verbal Abbreviated IQ (ABIQ) score of the Stanford-Binet Intelligence Scales, Fifth Edition (SB-5), or mental age of at least 18 months, as measured by the Cognitive and Adaptive Behavior subscales of the Developmental Profile (DP-4) Parent/Caregiver Interview form.
• Participation of a study partner who has consistent contact with the participant and is willing and able to attend visits, oversee the participant's compliance with the protocol and study medication, and report on the participant's status through study assessments.
• Participant reports ≥ 1 of the following:
• A diagnosed comorbid autoimmune disease (e.g., Crohn's disease, Graves' disease, Hashimoto's disease, psoriasis, rheumatoid arthritis, ulcerative colitis, type 1 diabetes mellitus, etc.).
• Current biomarker evidence of critical indicators of inflammation/autoimmunity, such as elevated levels of C-reactive protein (CRP) or abnormal value of antinuclear antibodies (ANA).
• A significant family history of autoimmunity, defined as having ≥ 1 first-degree relative or ≥ 2 second-degree relatives with autoimmune diseases. The Principal Investigator (PI) will make the final determination on this criterion.
• Any concomitant medications or interventions for ASD-related symptoms (e.g., alpha-2 agonists, anticonvulsants, antidepressants, antipsychotics, anxiolytics, gastrointestinal medications, medications for sleep disorders, probiotics, stimulants, behavioral therapies, psychosocial interventions, speech therapy, etc.) have been stable for at least 4 weeks prior to the screening visit and the participant/study partner intend to maintain a stable regimen throughout the trial.
• Participant can tolerate swallowing large capsules.
• Participant is willing and able, in the investigator's opinion, to comply with all study procedures.
• Individuals must satisfy the following criteria to be enrolled as study partners:
• The study partner is fluent in English.
• The study partner is a caregiver or an individual who has consistent contact with the participant, knows the participant well, and is willing and able to attend visits, oversee the participant's compliance with the protocol and study medication, and report on the participant's status through study assessments. The PI will make the final determination on this criterion.

You may not qualify if:

• DSM-5-TR diagnosed ASD, level 1, or presence of another DSM-IV-TR diagnosed pervasive developmental disorder, such as Asperger's disorder, childhood disintegrative disorder, Rett syndrome, or pervasive developmental disorder not otherwise specified (PDD-NOS). A qualified psychiatrist or psychologist will make a diagnostic determination after reviewing clinical history, clinical observations, medical records, mental status exams, and screening measures.
• A CGI-S rating \< 4 at screening (or baseline).
• A non-verbal IQ in the range of severe or profound intellectual disability (\< 35), as measured by the non-verbal ABIQ score of the SB-5, or mental age below 18 months, as measured by the Cognitive and Adaptive Behavior subscales of the DP-4 Parent/Caregiver Interview form. Individuals testing below 18 months may be enrolled after a case review by the PI and study psychologist, especially if testing scores were likely underestimated due to uncooperative behavior.
• Previous documentation of a prolonged electroencephalogram (EEG) suggestive of Landau-Kleffner syndrome or continuous spike and wave during sleep (CSWS) syndrome.
• Presence of a defined genetic disorder, such as Angelman syndrome, Fragile X syndrome, Noonan syndrome, Tuberous sclerosis, Williams syndrome, or any documented chromosomal or genetic abnormality with proven clinical significance in the etiology of ASD.
• Documented significant pre- or post-natal central nervous system insult, such as an in-utero cerebral vascular accident, that is believed to have significantly contributed to the development of the individual's ASD.
• Mitochondrial disorder verified by skin and/or muscle biopsy.
• Concomitant medications or interventions for ASD-related symptoms (e.g., alpha-2 agonists, anticonvulsants, antidepressants, antipsychotics, anxiolytics, gastrointestinal medications, medications for sleep disorders, probiotics, stimulants, behavioral therapies, psychosocial interventions, speech therapy, etc.) have not been stable for at least 4 weeks prior to the screening visit.
• An active bacterial, fungal, helminthic, protozoan, or viral infection that could be exacerbated by a course of prednisone, as determined by the PI.
• Significant medical findings from history, physical examination, or laboratory testing that may be incompatible with prednisone use (e.g., participants with chronic infectious conditions or unstable diabetes mellitus).
• Individuals with a history of seizures being treated with an anticonvulsant may be eligible if seizure-free for at least 6 months and the anticonvulsant dose has been stable for at least 4 weeks prior to the screening visit.
• Use of immunosuppressive agents within the 6 months prior to the screening visit or concurrent use of immunosuppressive agents that, in the judgment of the PI, would interfere with study outcomes or pose unreasonable risk with prednisone administration.
• A known hypersensitivity to prednisone or any other component of the study product.
• The participant is deemed unsuitable for any reason by the PI, including an inability to complete or comply with study requirements.
• Individuals may be excluded from enrollment as study partners if either of the following criteria are met:

Sponsors & Collaborators

• Christopher John McDougle, M.D.: lead

Study Sites (1)

MGH Lurie Center for Autism

Lexington, Massachusetts, 02421, United States

Location

MeSH Terms

Conditions

Autism Spectrum Disorder; Autistic Disorder; Autoimmune Diseases; Inflammation; Neuroinflammatory Diseases

Interventions

Prednisone

Condition Hierarchy (Ancestors)

Child Development Disorders, Pervasive; Neurodevelopmental Disorders; Mental Disorders; Immune System Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Nervous System Diseases

Intervention Hierarchy (Ancestors)

Pregnadienediols; Pregnadienes; Pregnanes; Steroids; Fused-Ring Compounds; Polycyclic Compounds

Study Officials

• Christopher J McDougle, M.D.

  Massachusetts General Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Olivia DeMichaelis

CONTACT

781-860-1711; MGHPREDICT-ASD@mgb.org

Alex Cordova

CONTACT

781-860-1711; MGHPREDICT-ASD@mgb.org

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Masking Details: All participants, parents/legal guardians (i.e., study partners), site staff (including investigators), and outcomes assessors will be masked for the duration of the study. Investigative pharmacists (or designees) will be unmasked for randomization and treatment allocation. Emergency unmasking may occur at any time throughout the study in the event that knowledge of the actual treatment is absolutely essential for further management of the participant, to fulfill expedited reporting requirements, or if requested by the Data Safety and Monitoring Board (DSMB).
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Director, Lurie Center for Autism

Model Details: Participants will be randomized 1:1 to prednisone or placebo.

Study Record Dates

• First Submitted: April 3, 2025
• First Posted: April 18, 2025
• Study Start (Estimated): November 1, 2026
• Primary Completion (Estimated): July 1, 2028
• Study Completion (Estimated): February 1, 2029
• Last Updated: March 23, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)